Clinical trials: flow cytometry
Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY
The outcome of HMA-refractory patients with MDS or AML is dismal with a median survival of 5 months after failure, representing a significant unmet medical need due to the very limited treatment options.
- Trial name
- SAMBA (NCT02992860)
- Testing
- JNJ-56022473, Bone marrow analyses and CBC with differential, Flow cytometry analyses
- Where
- 10 sites in France, Germany
- Volunteers
- 25 people
- Sponsor
- GWT-TUD GmbH
AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
In this multicenter, upfront randomized phase II trial, all patients receive quizartinib in combination with HAM (high-dose cytarabine, mitoxantrone) during salvage therapy.
- Trial name
- Q-HAM (NCT03989713)
- Testing
- MRD-triggered arm, Prophylactic Arm
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Prof. Dr. Richard F Schlenk
Multiple Myeloma
CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma
Multiple myeloma is a type of blood cancer characterized by the abnormal growth of plasma cells in the bone marrow. Increasing evidence indicates that interactions between myeloma cells and the host immune-inflammatory response…
- Trial name
- NCT07823959
- Volunteers
- 60 people
- Sponsor
- Assiut University
B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
This phase I trial is studying the side effects of giving genetically engineered lymphocytes together with cyclophosphamide and aldesleukin in treating patients with relapsed or refractory mantle cell lymphoma or indolent B-cell…
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT00621452
- Testing
- therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
RATIONALE: Belinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving belinostat together with bortezomib may kill more cancer cells.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
- Trial name
- NCT01075425
- Testing
- bortezomib, belinostat, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Virginia Commonwealth University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
The aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary membranous nephropathy (MN).
- Conditions
- Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Membranous Nephropathy - THSD7A Induced
- Trial name
- NCT05894512
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Immune Thrombocytopenic Purpura, Splenectomy; Status
Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura
The aim of this study is to determine histological immunological parameters, sought on splenectomy pieces that may explain the failure or success of splenectomy in patients with ITP who had a splenectomy to treat their ITP(Immune…
- Trial name
- SPLENOTIR (NCT04056507)
- Testing
- Immunolabeling
- Volunteers
- 80 people
- Sponsor
- University Hospital, Bordeaux
Pancreatic Neoplasms
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
This phase I trial studies the side effects and optimal dose of PF-04136309 when given with combination chemotherapy (FOLFIRINOX; 5-fluorouracil, leucovorin, irinotecan, oxaliplatin) in treating patients with locally advanced or…
- Trial name
- NCT01413022
- Testing
- Oxaliplatin, Irinotecan, Leucovorin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Washington University School of Medicine
Neonatal SEPSIS
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis
Neonatal sepsis (NS) is a rather serious but relatively common health problem. Despite recent advances in the treatment of neonatal infection, mortality and comorbidities remain high.
- Trial name
- NCT03795285
- Testing
- Expression of neutrophil CD64
- Volunteers
- 50 people
- Sponsor
- Assiut University
Sepsis With Acute Organ Dysfunction
Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis
Septic shock is still a major cause of death in ICU. Sepsis diagnosis is linked with many clinical, hemodynamic and biological criteria which have a low sensitivity and specificity if they are considered separately.
- Trial name
- SEPTIFLUX2 (NCT01995448)
- Testing
- Blood test
- Where
- 9 sites in France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Limoges
Neoplasms
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein
Background: Some cancers, such as Hodgkin's disease, anaplastic large cell lymphoma and others, have a protein on the surface of the cancer cell called CD30.
- Trial name
- NCT00048880
- Testing
- HeFi-1 Monoclonal Antibody
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
RhA - Rheumatoid Arthritis
Adversity and Its Association With the Development and Expression of Rheumatic Diseases
Epidemiological evidence shows that adverse experiences, particularly, but not exclusively in childhood, are predictors of poor long-term health outcomes and certain social domains.
- Trial name
- RD (NCT06386380)
- Testing
- Rheumatic diseases Mistreatment Scale (RDMS), Routine assessment of patient index data 3 (RAPID-3), Health Assessment Questionnaire (HAQ)
- Volunteers
- 110 people
- Sponsor
- National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Healthy
T Cell Responses to Various Levels of Exercise Stress
The objective of this project is to quantify the immunoendocrine response to acute stress events combining both physical and psychological challenges.
- Trial name
- NCT06638684
- Testing
- Exercise
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Kansas
Hypospadias
USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias
Hypospadias is one of the common congenital malformation disorders in male children, with a ratio of about 1 to 300 in newborn boys.
- Trial name
- NCT07495176
- Testing
- Exsome
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Shanghai Children's Hospital
Breast Cancer, Cervical Cancer
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
RATIONALE: EF5 may detect the presence of oxygen in tumor cells and help plan effective cancer treatment. PURPOSE: Phase I trial to study the effectiveness of EF5 in detecting the presence of oxygen in tumor cells of patients who…
- Conditions
- Breast Cancer, Cervical Cancer, Head and Neck Cancer, Prostate Cancer
- Trial name
- NCT00004261
- Testing
- EF5, flow cytometry, fluorescent antibody technique
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Systemic Lupus Erythematosus (SLE)
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
The natural history of Systemic lupus erythematosus (SLE) is characterized by relapses or flares alternated with periods of remission.
- Trial name
- 3TR-SLE1 (NCT05458622)
- Testing
- Blood sample, Urine sample, Saliva sample
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Brest
Acute Myeloid Leukemia
Immune Checkpoint Receptors in AML-Leukemic Initiating Cells
This project aim at deciphering immune mechanisms that allow the immunoescape of AML initiating cells.
- Trial name
- ICAML-LIC (NCT03449745)
- Where
- France
- Volunteers
- 199 people
- Sponsor
- University Hospital, Bordeaux
Carotid Atherosclerosis
Individualized Physical Activity and Carotid Plaque Instability
Intraplaque hemorrhage (IPH) is one of the main features of the carotid plaque instability's and predictor of ischemic stroke. Benefits (on the basis on benefit/risk ratio) of the carotid endarterectomy remain unclear for stroke…
- Trial name
- PACAPh (NCT04053166)
- Testing
- individualized home-based physical activity, MRI, blood sampling
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Membranous Nephropathy
Autoreactive B Cells in Membranous Nephropathy
Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 receptor (PLA2R).
- Trial name
- PEPTIDE (NCT04095156)
- Testing
- In vitro assays.
- Where
- Italy
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research